Compare ABEO & XTER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ABEO | XTER |
|---|---|---|
| Founded | 1974 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.5M | 267.2M |
| IPO Year | 2005 | 2026 |
| Metric | ABEO | XTER |
|---|---|---|
| Price | $2.28 | $9.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $18.38 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 116.8K |
| Earning Date | 11-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 165.16 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,998,000.00 | N/A |
| Revenue This Year | $731.38 | N/A |
| Revenue Next Year | $129.85 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 258.18 | N/A |
| 52 Week Low | $2.30 | $9.77 |
| 52 Week High | $7.65 | $9.84 |
| Indicator | ABEO | XTER |
|---|---|---|
| Relative Strength Index (RSI) | 17.41 | 51.11 |
| Support Level | N/A | N/A |
| Resistance Level | $5.77 | $9.81 |
| Average True Range (ATR) | 0.30 | 0.01 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 2.26 | 57.14 |
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
Karman Line Acquisition Corp is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses.